These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24558225)

  • 1. SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.
    D'heygere F; George C; Habersetzer F; Tripathi D; Q Pan C; Giron JA; Schmitz M; Tatsch F
    Ann Hepatol; 2014; 13(2):303-4. PubMed ID: 24558225
    [No Abstract]   [Full Text] [Related]  

  • 2. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.
    Nelson DR; Zeuzem S; Andreone P; Ferenci P; Herring R; Jensen DM; Marcellin P; Pockros PJ; Rodríguez-Torres M; Rossaro L; Rustgi VK; Sepe T; Sulkowski M; Thomason IR; Yoshida EM; Chan A; Hill G
    Ann Hepatol; 2012; 11(1):15-31. PubMed ID: 22166557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
    Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
    Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
    [No Abstract]   [Full Text] [Related]  

  • 4. Boceprevir and peginterferon α-2b plus ribavirin therapy of HCV genotype 3 relapsers: A pilot study.
    Lee SS; Kilvert L; Liu H; Trepanier J
    Dig Liver Dis; 2016 Mar; 48(3):344. PubMed ID: 26459137
    [No Abstract]   [Full Text] [Related]  

  • 5. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
    Pockros PJ; Nelson D; Godofsky E; Rodriguez-Torres M; Everson GT; Fried MW; Ghalib R; Harrison S; Nyberg L; Shiffman ML; Najera I; Chan A; Hill G
    Hepatology; 2008 Aug; 48(2):385-97. PubMed ID: 18570306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Outcomes and Predictors of Response in Treatment-Naive HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHESYS Cohort.
    Ascione A; Bruno S; Coppola C; Mangia A; Orlandini A; Schmitz M; Deodato B; Puoti M
    Hepatogastroenterology; 2014 Jun; 61(132):1094-106. PubMed ID: 26158171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
    Fried MW; Jensen DM; Rodriguez-Torres M; Nyberg LM; Di Bisceglie AM; Morgan TR; Pockros PJ; Lin A; Cupelli L; Duff F; Wang K; Nelson DR
    Hepatology; 2008 Oct; 48(4):1033-43. PubMed ID: 18697207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
    Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
    J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
    Gane EJ; Rouzier R; Stedman C; Wiercinska-Drapalo A; Horban A; Chang L; Zhang Y; Sampeur P; Nájera I; Smith P; Shulman NS; Tran JQ
    J Hepatol; 2011 Nov; 55(5):972-9. PubMed ID: 21354234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.
    Marcellin P; Cheinquer H; Curescu M; Dusheiko GM; Ferenci P; Horban A; Jensen D; Lengyel G; Mangia A; Ouzan D; Puoti M; Rodriguez-Torres M; Shiffman ML; Schmitz M; Tatsch F; Rizzetto M
    Hepatology; 2012 Dec; 56(6):2039-50. PubMed ID: 22706730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin.
    Ferenci P; Aires R; Ancuta I; Arohnson A; Cheinquer H; Delic D; Gschwantler M; Larrey D; Tallarico L; Schmitz M; Tatsch F; Ouzan D
    Liver Int; 2014 Nov; 34(10):1550-9. PubMed ID: 24329937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin.
    Zeuzem S; Rodríguez-Torres M; Rajender Reddy K; Marcellin P; Diago M; Craxi A; Pockros P; Rizzetto M; Bernstein D; Shiffman ML; Lin A; Tatsch F; Hadziyannis S
    J Viral Hepat; 2012 Nov; 19(11):766-74. PubMed ID: 23043383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort.
    Aronsohn A; Ancuta I; Caruntu F; Coppola C; Delic D; Digiacomo A; Dusheiko GM; Lengyel G; Marcellin P; Orlandini A; Pruthi J; Silva GF; Tallarico L; Schmitz M; Tatsch F; Korner E; Cheinquer H
    J Viral Hepat; 2014 May; 21(5):377-80. PubMed ID: 24131506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
    Ferenci P; Laferl H; Scherzer TM; Maieron A; Hofer H; Stauber R; Gschwantler M; Brunner H; Wenisch C; Bischof M; Strasser M; Datz C; Vogel W; Löschenberger K; Steindl-Munda P;
    Gastroenterology; 2010 Feb; 138(2):503-12, 512.e1. PubMed ID: 19909752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
    N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
    Harrison SA; Abdurakhmanov D; Shiffman ML; Bakulin I; Mazur W; Rodriguez-Torres M; Silva GF; Cheinquer H; Messinger D; Connell EV; McKenna M; Tatsch F; Reddy KR;
    J Clin Gastroenterol; 2013 Mar; 47(3):271-9. PubMed ID: 22951527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.
    Mangia A; Bányai T; De Bartolomeo G; Gervain J; Habersetzer F; Mulkay JP; Ouzan D; Parruti G; Passariello N; Remy AJ; Rizzetto M; Shiffman ML; Tice AD; Schmitz M; Tatsch F; Rodriguez-Torres M
    Liver Int; 2014 Aug; 34(7):e217-28. PubMed ID: 24251988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1.
    Izumi N; Yokosuka O; Kawada N; Osaki Y; Yamamoto K; Sata M; Ishikawa H; Ueki T; Hu W; McPhee F; Hughes EA; Kumada H
    Antivir Ther; 2014; 19(5):501-10. PubMed ID: 24451151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels.
    Calleja JL; García-Samaniego J; Ruiz-Antorán B; Trapero M; Morillas R; de la Revilla J; Erdozaín JC; Espinosa MD; Suárez D; Solá R; Romero-Gómez M; Baños F; Alvarez MA;
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1705-10. PubMed ID: 22742958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.